• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis Ag ADR (NY: NVS )

    116.39 +0.02 (+0.01%)
    Streaming Delayed Price Updated: 3:47 PM EDT, Sep 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 758,050
    Open 115.84
    Bid (Size) 116.38 (3)
    Ask (Size) 116.39 (2)
    Prev. Close 116.37
    Today's Range 115.43 - 116.48
    52wk Range 92.19 - 120.92
    Shares Outstanding N/A
    Dividend Yield 2.98%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures Product Safety
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    From FN Media Group LLC
    Via GlobeNewswire

    Performance

    YTD
    +15.23%
    +15.23%
    1 Month
    -2.32%
    -2.32%
    3 Month
    +8.82%
    +8.82%
    6 Month
    +21.58%
    +21.58%
    1 Year
    +14.32%
    +14.32%

    More News

    Read More
    Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
    Via Chartmill
    NYSE:NVS: good value for what you're paying.
    Via Chartmill
    Uncovering Dividend Opportunities with NYSE:NVS.
    Via Chartmill
    Embassy of Italy in Singapore Presents ‘Superstar’ Architect Michele De Lucchi for Singapore Design Week 2024
    Via AB Newswire
    How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
    Via FinancialNewsMedia
    How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
    From FN Media Group LLC
    Via GlobeNewswire
    2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
    Via Investor's Business Daily
    Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
    Via Benzinga
    Time To Invest And Or Trade In Bio-Tech Stocks?
    Via Talk Markets
    Topics ETFs
    This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
    Via Benzinga
    Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
    Via Benzinga
    Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
    Via Benzinga
    S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
    Via Benzinga
    Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
    From Lindy Biosciences
    Via Business Wire
    Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
    Via Investor's Business Daily
    Exposures Product Safety
    Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
    Via Benzinga
    2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
    Via The Motley Fool
    Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
    Via Benzinga
    The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
    Via Newsfile
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.